Through the collaboration Biovitrum gains access to the proprietary technology platforms of Affibody molecules, as well as the unique albumin-binding technology for pharmaceuticals development.
The agreement consists of a defined protein target development collaboration and a product licensing agreement. Costs associated with the collaboration will be absorbed within Biovitrum’s capped running R&D budget.
Affibody molecules are small stable proteins that can have the same effects as large proteins, and in addition have potential efficacy, safety, administration route and price benefits. The albumin-binding technology is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life.
David Bejker, president and CEO of Affibody, said: “This collaboration with Biovitrum represents an important step in Affibody’s efforts to become profitable within the coming two years. It is the first collaboration with our novel biopharmaceutical concept, based on the Second Generation Affibody molecules and the second generation of our albumin binding technology. We believe that Biovitrum is an ideal partner for the development and commercialization of products based on our technology platforms.”